The Endeavor stent is the first of a new generation of drug-eluting stents and is viewed by doctors as an important improvement. Use of early model drug-eluting stents has slowed since 2006 due to concerns about their long-term safety. Extensive clinical data show the Endeavor stent effective at reducing restenosis (the renarrowing of the treated artery) with excellent long-term results.
Drug-eluting stents were developed to further prevent reclosure of the artery by using a drug coating on the stent to slow the growth of excessive tissue as the artery wall heals after the procedure. The Endeavor stent utilizes a lower profile alloy that enables rapid and complete elution of the drug into the surrounding tissue more effectively than previous stents.
The Endeavor stent was approved by the FDA on Feb. 1, 2008, and was first used at MeritCare by cardiologist Dr. Thomas Haldis on Feb. 6.
- CAD is a narrowing and hardening of the small coronary arteries that supply blood to the heart, which restricts blood supply and leads to chest pain and heart attacks. A common minimally invasive treatment for CAD is angioplasty, a procedure used to open blocked or narrowed coronary arteries with a balloon that is threaded into the blocked artery along a catheter. A tiny mesh cylinder known as a stent is usually placed in the artery to keep it propped open after the procedure.
- Coronary angioplasty with drug-eluting stents has been shown to be superior to angioplasty using only a balloon or bare-metal stent.
- The Endeavor stent is manufactured by Medtronic, Inc., Minneapolis.